In other recent news, Neurocrine Biosciences has made significant strides with the FDA approval and subsequent launch of its novel treatment, Crenessity, for congenital adrenal hyperplasia (CAH ...

Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Ashley Allan is making history in her role as executive director for CAH brand marketing at Neurocrine Biosciences, overseeing a cross-functional team that launched the first treatment for CAH (a ...

Of the trio, the most drastic cutter was UBS's Ashwani Verma, who reduced his level on Neurocrine to $154 per share from his preceding $176. According to reports, Verma cited uninspiring guidance ...

Neurocrine Biosciences emphasizes the importance of this development for individuals with CAH and their families, as well as healthcare providers. The new treatment options represent an advancement in ...

CEO Kyle Gano highlighted Neurocrine's transformation into a fully ... citing its groundbreaking profile for congenital adrenal hyperplasia (CAH). CFO Matt Abernethy projected INGREZZA sales ...

Good day, everyone, and welcome to today's Neurocrine Biosciences reports Q4 and fiscal year 2024 Earnings Call. (Operator Instructions) Please note today's call will be recorded and I will be ...

BMO Capital analyst Evan Seigerman maintained a Hold rating on Neurocrine (NBIX – Research ... Crinessity in congenital adrenal hyperplasia (CAH), the data on patient starts and revenue is ...

This educational supplement is based on a press release statement from Neurocrine Biosciences and aims to enhance clinical practice and patient care for those affected by classic CAH. According to ...

SAN DIEGO - Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has sponsored a supplement in The Journal of Clinical Endocrinology & Metabolism (JCEM) focusing on classic congenital adrenal hyperplasia (CAH), ...